Saylor P, Kaufman D, Michaelson D, Lee R, Smith M. Application of the WHO/FRAX fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. Journal of Urology. 2010 Jun; 183(6):2200-5.
Saylor P, Fogerty A. Prostate cancer associated hypercoagulability: do we need to worry about androgen deprivation? Lancet Oncology. 2010 May; 11(5):406-7.
Saylor P, Smith M. Adverse Effects of Androgen Deprivation Therapy: Defining the Problem and Promoting Health among Men with Prostate Cancer. Journal of the National Comprehensive Cancer Network. 2010 Feb; 8(2): 211-23.
Saylor P, Smith M. Review: Bone Health and Prostate Cancer. Prostate Cancer and Prostatic Diseases. 2009 Mar; 13(1):20-7.
Saylor P, Keating N, Smith M. Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy. Journal of General Internal Medicine. 2009 Nov; 24(2): 389-94.
Saylor P, Smith M. Prostate Cancer: How can we improve the health of men who receive ADT? Nature Reviews Urology. 2009 Oct; 6(10): 529-31.
Saylor P, Michaelson M. New Treatments for Renal Cell Carcinoma: Targeted Therapies. Journal of the National Comprehensive Cancer Network. 2009; 7(6): 645-56.
Saylor P, Smith M. Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology. 2009 May; 181 (5): 1998-2006.
Saylor P, Reid T. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. Journal of Clinical Oncology. 2007 Aug 10; 25 (23): 3544-3546.
Phone 2: 617-726-8689